Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 701–800 of 1,008
Rolinski, M., Zokaei, N., Baig, F., Giehl, K., Quinnell, T. G., Zaiwalla, Z., Mackay, C. E., Husain, M., & Hu, M. T. M. (2015) · Brain · doi:10.1093/brain/awv334 · Cited by 48
Goldstein, O., Gana‐Weisz, M., Cohen-Avinoam, D., Shiner, T., Thaler, A., Cedarbaum, J. M., John, S., Lalioti, M. D., Gurevich, T., Bar‐Shira, A., et al. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.10.001 · Cited by 44
Self-citationWhole-exome sequencing in early-onset Parkinson's disease among ethnic Chinese
Li, N., Wang, L., Zhang, J., Tan, E., Li, J., Peng, J., Duan, L., Chen, C., Zhou, D., He, L., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.023 · Cited by 48
Self-citationGaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?
Dinur, T., Bauer, P., Beetz, C., Kramp, G. J., Cozma, C., Iurascu, M. I., Becker‐Cohen, M., Istaiti, M., Rolfs, A., Zimran, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031627 · Cited by 46
Self-citationDrobny, A., Boros, F. A., Balta, D., Huarcaya, S. P., Caylioglu, D., Qazi, N., Vandrey, J., Schneider, Y., Dobert, J. P., Pitcairn, C., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00363-z · Cited by 48
Zhao, P., Wu, T., Tian, Y., You, J. E., & Cui, X. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115323 · Cited by 48
GBA1-Associated Parkinson’s Disease Is a Distinct Entity
Skrahin, A., Horowitz, M., Istaiti, M., Skrahina, V., Lukáš, J., Yahalom, G., Cohen, M. E., Revel‐Vilk, S., Göker-Alpan, Ö., Becker‐Cohen, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137102 · Cited by 48
Self-citationParkinson's disease, proteins, and prions: Milestones
Olanow, C. W., & McNaught, K. S. P. (2011) · Movement Disorders · doi:10.1002/mds.23767 · Cited by 55
Artola, M., Kuo, C. J., Lelieveld, L. T., Rowland, R. J., van der Marel, G. A., Codée, J. D. C., Boot, R. G., Davies, G. J., Aerts, J. M. F. G., & Overkleeft, H. S. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b00056 · Cited by 43
Akiyama, H., Ide, M., Nagatsuka, Y., Sayano, T., Nakanishi, E., Uemura, N., Yuyama, K., Yamaguchi, Y., Kamiguchi, H., Takahashi, R., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.012502 · Cited by 46
“Exosomes have been hypothesized to participate in transferring pathogenic proteins between cells (40), such as -amyloid peptide and -synuclein, known to be associated with PD and MSA.”
BackgroundInfluentialGlajch, K. E., Moors, T. E., Chen, Y., Bechade, P. A., Nam, A. Y., Rajsombath, M. M., McCaffery, T. D., Dettmer, U., Weihofen, A., Hirst, W. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103425118 · Cited by 45
Yu, Z., Wang, T., Xu, J., Wang, W., Wang, G., Chen, C., Zheng, L., Li, P., Gong, D., Li, X., et al. (2014) · Journal of Human Genetics · doi:10.1038/jhg.2014.110 · Cited by 47
Self-citationPLA2G6 variant in Parkinson's disease
Tomiyama, H., Yoshino, H., Ogaki, K., Li, L., Yamashita, C., Li, Y., Funayama, M., Sasaki, R., Kokubo, Y., Kuzuhara, S., et al. (2011) · Journal of Human Genetics · doi:10.1038/jhg.2011.22 · Cited by 43
Genetics of movement disorders in the next‐generation sequencing era
Olgiati, S., Quadri, M., & Bonifati, V. (2016) · Movement Disorders · doi:10.1002/mds.26521 · Cited by 45
The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies
Gan‐Or, Z., Orr‐Urtreger, A., Alcalay, R. N., Bressman, S., Giladi, N., & Rouleau, G. A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.018 · Cited by 43
Self-citationGarcía‐Moreno, M. I., de la Mata, M., Sánchez‐Fernández, E. M., Benito, J. M., Díaz-Quintana, A., Fustero, S., Nanba, E., Higaki, K., Sánchez-Alcázar, J. A., Fernández, J. M. G., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01550 · Cited by 44
Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
Schneider, S. A., Hizli, B., & Alcalay, R. N. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00920-8 · Cited by 44
“More than 300 mutations in GBA have been reported [51], and they are traditionally divided based on the GD phenotype they are associated with.”
BackgroundAvenali, M., Cerri, S., Ongari, G., Ghezzi, C., Pacchetti, C., Tassorelli, C., Valente, E. M., & Blandini, F. (2021) · Movement Disorders · doi:10.1002/mds.28496 · Cited by 44
Evaluation of Strategies for Measuring Lysosomal Glucocerebrosidase Activity
Ysselstein, D., Young, T. J., Nguyen, M. N., Padmanabhan, S., Hirst, W. D., Dzamko, N. L., & Krainc, D. (2021) · Movement Disorders · doi:10.1002/mds.28815 · Cited by 46
GBA mutations, glucosylceramide and Parkinson's disease
Milenković, I., Blumenreich, S., & Futerman, A. H. (2021) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.11.004 · Cited by 49
Biomarkers of Parkinson's disease and Dementia with Lewy bodies
Henchcliffe, C., Dodel, R. C., & Beal, M. F. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.09.002 · Cited by 48
Astrocytes and lysosomal storage diseases
Rao, K. V. R., & Kielian, T. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.061 · Cited by 49
“PD patients harboring a GBA mutation had an earlier disease onset (on average 4 years earlier) and were more likely to experience atypical clinical disease, making GBA mutations among the most common genetic risk factors for PD identified to date (Sidransky et al., 2009a).”
BackgroundThe significance of GBA for Parkinson's disease
Brockmann, K., & Berg, D. (2014) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9714-7 · Cited by 45
Self-citationWhole-exome sequencing associates novelCSMD1gene mutations with familial Parkinson disease
Ruiz-Martínez, J., Azcona, L. J., Bergareche, A., Martí-Massó, J. F., & Paisán‐Ruiz, C. (2017) · Neurology Genetics · doi:10.1212/nxg.0000000000000177 · Cited by 41
Emerging links between pediatric lysosomal storage diseases and adult parkinsonism
Ysselstein, D., Shulman, J. M., & Krainc, D. (2019) · Movement Disorders · doi:10.1002/mds.27631 · Cited by 40
“Heterozygous mutations in the GBA1 gene are the most common genetic risk factor for PD with a predicted frequency of 7% to 10% in the PD population.(12) This is an example of genetic pleiotropy, by which variation in a single gene (GBA1) can influence multiple, distinct clinical phenotypes (GD and PD), through autosom…”
BackgroundResultKoster, K. P., Francesconi, W., Berton, F., Alahmadi, S., Srinivas, R., & Yoshii, A. (2019) · eLife · doi:10.7554/elife.40316 · Cited by 42
Impaired cellular bioenergetics caused by GBA1 depletion sensitizes neurons to calcium overload
Plotegher, N., Perocheau, D. P. B., Ferrazza, R., Massaro, G., Bhosale, G., Zambon, F., Rahim, A. A., Guella, G., Waddington, S. N., Szabadkai, G., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0442-2 · Cited by 43
Biomarkers and the Role of α-Synuclein in Parkinson’s Disease
Du, T., Wang, L., Liu, W., Zhu, G., Chen, Y., & Zhang, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.645996 · Cited by 44
Leocadi, M., Canu, E., Donzuso, G., Stojković, T., Basaia, S., Kresojević, N. D., Stanković, I., Sarasso, E., Piramide, N., Tomić, A., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10713-4 · Cited by 45
Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
Omer, N., Giladi, N., Gurevich, T., Bar‐Shira, A., Gana‐Weisz, M., Glinka, T., Goldstein, O., Kestenbaum, M., Cedarbaum, J. M., Mabrouk, O. S., et al. (2021) · Movement Disorders · doi:10.1002/mds.28792 · Cited by 49
Self-citationSepúlveda, D., Cisternas-Olmedo, M., Arcos, J., Nassif, M., & Vidal, R. L. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.805087 · Cited by 42
“Heterozygous mutations in the GBA1 gene encoding lysosomal enzyme GCase are strong risk factors for PD (Avenali et al., 2020).”
BackgroundInfluentialHyperferritinemia and iron metabolism in Gaucher disease: Potential pathophysiological implications
Regenboog, M., Kuilenburg, A. B. P., Verheij, J., Swinkels, D. W., & Hollak, C. E. M. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.05.003 · Cited by 44
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson’s disease
Senkevich, K., Zorca, C. E., Dworkind, A., Rudakou, U., Somerville, E., Yu, E., Ermolaev, A., Nikanorova, D., Ahmad, J., Ruskey, J. A., et al. (2023) · Brain · doi:10.1093/brain/awac413 · Cited by 40
Self-citationRosh, I., Tripathi, U., Hussein, Y., Rike, W. A., Djamus, J., Shklyar, B., Manole, A., Houlden, H., Winkler, J., Gage, F. H., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00653-x · Cited by 45
Alzheimer’s Genetics in the GWAS Era: A Continuing Story of ‘Replications and Refutations’
Bertram, L. (2011) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-011-0193-z · Cited by 46
“One example for a “rare variant association” in the neurodegenerative disease field is the N370S amino-acid substitution in GBA (glucosidase, beta, acid) in PD [ 33 ].”
BackgroundThe ceramide transporter and the Goodpasture antigen binding protein: one protein – one function?
Mencarelli, C., Losen, M. H., Hammels, C., Vry, J. D., Hesselink, M. K. C., Steinbusch, H. W. M., Baets, M. H. D., & Martínez‐Martínez, P. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06673.x · Cited by 45
The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease
Malec-Litwinowicz, M., Plewka, A., Plewka, D., Bogunia, E., Morek, M., Szczudlik, A., Szubiga, M., & Rudzińska-Bar, M. (2018) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2017.11.009 · Cited by 41
Deep brain stimulation and genetic variability in Parkinson’s disease: a review of the literature
Ligaard, J., Sannæs, J., & Pihlstrøm, L. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0091-7 · Cited by 44
Autophagic- and Lysosomal-Related Biomarkers for Parkinson’s Disease: Lights and Shadows
Xicoy, H., Peñuelas, N., Vila, M., & Laguna, A. (2019) · Cells · doi:10.3390/cells8111317 · Cited by 43
“First, 7–10% of PD patients considered as sporadic (sPD) are actually carriers of GBA mutations (GBA-PD) [30,34,35].”
BackgroundMarotta, N., Kim, S., & Krainc, D. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1703671 · Cited by 42
“(N370S and L444P) account for ~3% of GBA-liked PD [117,123].”
BackgroundHigh Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease
Klatt‐Schreiner, K., Valek, L., Kang, J., Khlebtovsky, A., Trautmann, S., Hahnefeld, L., Schreiber, Y., Gurke, R., Thomas, D., Wilken‐Schmitz, A., et al. (2020) · Movement Disorders · doi:10.1002/mds.28186 · Cited by 41
“Above endocannabinoids, recent research has strengthened the idea of pathogenic lipid allostasis owing to the discovery of heterozygous mutations of the lipid-degrading enzyme glucocerebrosidase (GBA1) in association with early-onset and rapidly progressive sporadic PD.(32-35) Importantly, in vitro models revealed tha…”
BackgroundGenetics of Parkinson disease and essential tremor
Wider, C. W., Ross, O. A., & Wszołek, Z. K. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32833b1f4c · Cited by 46
The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease
Linnertz, C. L., Lutz, M. W., Ervin, J. F., Allen, J., Miller, N. R., Welsh-Bohmer, K. A., Roses, A. D., & Chiba‐Falek, O. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu196 · Cited by 44
White matter abnormalities in Parkinson's disease patients with glucocerebrosidase gene mutations
Agosta, F., Kostić, V., Davidović, K., Kresojević, N. D., Sarro, L., Svetel, M. V., Stanković, I., Comı, G., Klein, C., & Filippi, M. (2013) · Movement Disorders · doi:10.1002/mds.25397 · Cited by 43
Trifonova, O. P., Maslov, D. L., Balashova, E. E., Рашидовна, У. Г., Абаимов, Д. А., Fedotova, E. Y., Poleschuk, V. V., Illarioshkin, S. N., & Lokhov, P. G. (2020) · Diagnostics · doi:10.3390/diagnostics10050339 · Cited by 46
Rosety, I., Žagare, A., Saraiva, C., Nickels, S., Antony, P. M. A., Serra-Almeida, C., Glaab, E., Halder, R., Velychko, S., Rauen, T., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00616-8 · Cited by 46
Towards a Global View of Parkinson's Disease Genetics
Khani, M., Cerquera‐Cleves, C., Kekenadze, M., Crea, P. W., Singleton, A., & Bandrés‐Ciga, S. (2024) · Annals of Neurology · doi:10.1002/ana.26905 · Cited by 40
“111,112 These pathogenic variants impair glucocerebrosidase function, reducing enzymatic activity and potentially heightening alpha-synuclein aggregation.”
BackgroundSelf-citationRecent developments in gene therapy for Parkinson’s disease
Szunyogh, S., Carroll, E., & Wade‐Martins, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.030 · Cited by 45
Zhang, Y., Sun, Q., Zhao, Y., Li, S., Guo, J., Xu, Q., Yan, X., & Tang, B. (2015) · Parkinson s Disease · doi:10.1155/2015/916971 · Cited by 43
Self-citationEnvironmental-Genetic Interactions in the Pathogenesis of Parkinson's Disease
Tsuboi, Y. (2012) · Experimental Neurobiology · doi:10.5607/en.2012.21.3.123 · Cited by 39
Nonmotor Signs in Genetic Forms of Parkinson's Disease
Kasten, M., Marras, C., & Klein, C. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.05.030 · Cited by 41
Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course
Tayebi, N., Parisiadou, L., Berhe, B. A., Gonzalez, A. N., Serra‐Vinardell, J., Tamargo, R., Maniwang, E., Sorrentino, Z. A., Fujiwara, H., Grey, R. J., et al. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.11.001 · Cited by 41
Self-citationα-Synuclein interacts directly but reversibly with psychosine: implications for α-synucleinopathies
Abdelkarim, H., Marshall, M. S., Scesa, G., Smith, R. A., Rue, E. A., Marshall, J. N., Elackattu, V., Stoskute, M., Issa, Y., Santos, M. B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30808-9 · Cited by 41
Neurological effects of glucocerebrosidase gene mutations
Mullin, S., Hughes, D. A., Mehta, A. B., & Schapira, A. H. V. (2018) · European Journal of Neurology · doi:10.1111/ene.13837 · Cited by 40
“Equally, specific mutations which are known to be highly pathogenic in terms of nGD (such as L444P) [77] are also amongst the most pathogenic in terms of PD risk [78].”
Current Update on Clinically Relevant Sleep Issues in Parkinson’s Disease: A Narrative Review
Suzuki, K. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202425 · Cited by 45
Sucunza, D., Rico, A. J., Roda, E., Collantes, M., González‐Aseguinolaza, G., Rodriguez-Perez, A. I., Peñuelas, I., Vázquez, A., Labandeira-García, J. L., Broccoli, V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094825 · Cited by 41
microRNAs involved in Parkinson's disease: A systematic review
Da Silva, F. C., Da Rosa Iop, R., Vietta, G. G., Kair, D. A., Filho, P. J. B. G., Souza De Alvarenga, J. G., & Da Silva, R. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5759 · Cited by 38
The Transcellular Propagation and Intracellular Trafficking of α-Synuclein
Tofaris, G. K., Goedert, M., & Spillantini, M. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024380 · Cited by 41
Genetics of Parkinson's Disease: From Causes to Treatment
Westenberger, A., Brüggemann, N., & Klein, C. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041774 · Cited by 42
Epidemiology of atypical parkinsonian syndromes
Lo, R. Y. (2021) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_218_20 · Cited by 50
Tsukita, K., Sakamaki‐Tsukita, H., Kaiser, S., Zhang, L., Messa, M., Serrano‐Fernández, P., & Takahashi, R. (2023) · Neurology · doi:10.1212/wnl.0000000000207725 · Cited by 44
Classification and Genotype–Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review
Rossi, M., Schaake, S., Usnich, T., Boehm, J., Steffen, N., Schell, N., Krüger, C., Gül, T., Bahr, N., Kleinz, T., et al. (2025) · Movement Disorders · doi:10.1002/mds.30141 · Cited by 42
Self-citationImpaired mitochondrial homeostasis and neurodegeneration: towards new therapeutic targets?
Corona, J. C., & Duchen, M. R. (2014) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-014-9576-6 · Cited by 42
Clinical course and prognosis in patients with Gaucher disease and parkinsonism
Lopez, G., Kim, J., Wiggs, E., Cintron, D., Groden, C., Tayebi, N., Mistry, P. K., Pastores, G. M., Zimran, A., Goker-Alpan, O., et al. (2016) · Neurology Genetics · doi:10.1212/nxg.0000000000000057 · Cited by 37
Self-citationCornejo‐Olivas, M., Torres, L., Velit-Salazar, M. R., Inca‐Martinez, M., Mazzetti, P., Cosentino, C., Micheli, F. E., Perandones, C., Diéguez, E., Raggio, V. E., et al. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0020-6 · Cited by 38
Self-citationNew Frontiers in Parkinson's Disease: From Genetics to the Clinic
Shihabuddin, L. S., Brundin, P., Greenamyre, J. T., Stephenson, D. T., & Sardi, S. P. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.1666-18.2018 · Cited by 40
Indellicato, R., & Trinchera, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133304 · Cited by 38
“A very intriguing issue in this field is the epidemiological evidence, established about 10 years ago, that GBA mutations are the major genetic risk factors for the development of PD in elderly people [51].”
BackgroundThe Challenge of Disease-Modifying Therapies in Parkinson’s Disease: Role of CSF Biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Biomolecules · doi:10.3390/biom10020335 · Cited by 43
“Homozygous or compound heterozygous mutations in the GBA gene cause Gaucher’s disease (GD), a lysosomal storage disorder with an autosomal recessive inheritance [28], whereas heterozygous mutations represent the most common genetic risk factor for PD [27].”
BackgroundPetit, C. S. V., Lee, J. J., Boland, S., Swarup, S., Christiano, R., Lai, Z. W., Mejhert, N., Elliott, S. D., McFall, D. J., Haque, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1913956117 · Cited by 39
The role of lipids in autophagy and its implication in neurodegeneration
Hernández-Díaz, S., & Soukup, S. (2020) · Cell Stress · doi:10.15698/cst2020.07.225 · Cited by 42
Maple‐Grødem, J., Dalen, I., Tysnes, O., Macleod, A. D., Forsgren, L., Counsell, C. E., & Alves, G. W. (2020) · Neurology · doi:10.1212/wnl.0000000000011411 · Cited by 38
Macrophages derived from pluripotent stem cells: prospective applications and research gaps
Lyadova, I. V., & Vasiliev, A. V. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00824-4 · Cited by 40
Leyns, C. E. G., Prigent, A., Beezhold, B., Yao, L., Hatcher, N. G., Tao, P., Kang, J. J., Suh, E. R., Deerlin, V. M. V., Trojanowski, J. Q., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00517-w · Cited by 42
Huang, C., Chou, Y. W., Lai, S. ‐., Chang, H. ‐., Yeh, T. ‐., Weng, Y.-H., Chen, R. ‐., Huang, Y., & Lu, C. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03362.x · Cited by 41
Vesicular Dysfunction and the Pathogenesis of Parkinson’s Disease: Clues From Genetic Studies
Ebanks, K., Lewis, P. A., & Bandopadhyay, R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01381 · Cited by 36
Allende, M. L., Zhu, H., Kono, M., Hoachlander-Hobby, L. E., Huso, V. L., & Proia, R. L. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109879 · Cited by 37
GBA -associated PD: Neurodegeneration, altered membrane metabolism, and lack of energy failure
Brockmann, K., Hilker, R., Pilatus, U., Baudrexel, S., Srulijes, K., Magerkurth, J., Hauser, A., Schulte, C., Csóti, I., Merten, C. D., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31825dd369 · Cited by 38
Self-citationOffman, M. N., Król, M., Silman, I., Sussman, J. L., & Futerman, A. H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172098 · Cited by 37
Sauerbier, A., Jitkritsadakul, O., Titova, N., Klingelhoefer, L., Tsuboi, Y., Carr, H. J., Kumar, H., Banerjee, R., Erro, R., Bhidayasiri, R., et al. (2017) · Neuroepidemiology · doi:10.1159/000478702 · Cited by 45
Li, J., Ruskey, J. A., Arnulf, I., Dauvilliers, Y. A., Hu, M. T. M., Högl, B., Leblond, C. S., Zhou, S., Ambalavanan, A., Ross, J. P., et al. (2018) · Movement Disorders · doi:10.1002/mds.27385 · Cited by 43
Self-citationLelieveld, L. T., Mirzaian, M., Kuo, C. J., Artola, M., Ferraz, M. J., Peter, R. E. A., Akiyama, H., Greimel, P., van den Berg, R. J. B. H. N., Overkleeft, H. S., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.ra119000154 · Cited by 37
“of such a mutation, have a markedly increased risk for developing Parkinson’s disease and Lewy-body dementia (5, 6).”
BackgroundProdromal PD: A new nosological entity
Schaeffer, E., Postuma, R. B., & Berg, D. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2020.01.003 · Cited by 41
Self-citationGCase Enhancers: A Potential Therapeutic Option for Gaucher Disease and Other Neurological Disorders
Martínez‐Bailén, M., Clemente, F., Matassini, C., & Cardona, F. (2022) · Pharmaceuticals · doi:10.3390/ph15070823 · Cited by 37
From Lysosomal Storage Disorders to Parkinson’s Disease – Challenges and Opportunities
Mächtel, R., Boros, F. A., Dobert, J. P., Arnold, P., & Zunke, F. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167932 · Cited by 39
Physiological and pathological functions of LRRK2: implications from substrate proteins
Araki, M., Ito, G., & Tomita, T. (2018) · Neuronal Signaling · doi:10.1042/ns20180005 · Cited by 39
Parkinson’s VPS35[D620N] mutation induces LRRK2-mediated lysosomal association of RILPL1 and TMEM55B
Pal, P., Taylor, M., Lam, P. Y., Tonelli, F., Hecht, C. A., Lis, P., Nirujogi, R. S., Phung, T. K., Yeshaw, W. M., Jaimon, E., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj1205 · Cited by 36
The Role of Chaperone-Mediated Autophagy in Tissue Homeostasis and Disease Pathogenesis
Valdor, R., & Martínez‐Vicente, M. (2024) · Biomedicines · doi:10.3390/biomedicines12020257 · Cited by 44
“The first genetic risk factor for PD is the presence of a mutation in the GBA gene [70,71].”
BackgroundMultiple system atrophy: an update and emerging directions of biomarkers and clinical trials
Liu, M., Wang, Z., & Shang, H. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12269-5 · Cited by 39
Pathogenesis of Parkinson’s Disease
Xiao, B., Zhou, Z., Chao, Y., & Tan, E.-K. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2024.12.003 · Cited by 77
Self-citationCurrent understanding and management of Parkinson disease: Five new things
Morley, J. F., & Hurtig, H. I. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fb3628 · Cited by 43
Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients
Malec‐Litwinowicz, M., Rudzińska, M., Szubiga, M., Michalski, M., Tomaszewski, T., & Szczudlik, A. (2014) · Neurologia i Neurochirurgia Polska · doi:10.1016/j.pjnns.2014.07.005 · Cited by 37
Dodge, J. C. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00356 · Cited by 32
Kumar, D. T., Eldous, H. G., Mahgoub, Z. A., Doss, C. G. P., & Zayed, H. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0286-3 · Cited by 37
Modeling Parkinson’s Disease Using Induced Pluripotent Stem Cells
Hu, X., Mao, C., Fan, L., Luo, H., Hu, Z., Zhang, S., Yang, Z., Zheng, H., Sun, H., Fan, Y., et al. (2020) · Stem Cells International · doi:10.1155/2020/1061470 · Cited by 42
“The GBA mutation is the strongest risk gene for PD [109].”
BackgroundPolygenic Risk Scores Contribute to Personalized Medicine of Parkinson’s Disease
Dehestani, M., Liu, H., & Gasser, T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11101030 · Cited by 41
Self-citationLim, J. L., Lohmann, K., Tan, A. H., Tay, Y. W., Ibrahim, K. A., Aziz, Z. A., Mawardi, A. S., Puvanarajah, S. D., Lim, T. T., Looi, I., et al. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02421-0 · Cited by 37
Self-citationRetinal thinning in Gaucher disease patients and carriers: Results of a pilot study
McNeill, A., Roberti, G., Lascaratos, G., Hughes, D. A., Mehta, A. B., Garway‐Heath, D. F., & Schapira, A. H. V. (2013) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.04.001 · Cited by 36
NMR Metabolomics Analysis of Parkinson's Disease
Lei, S., & Powers, R. (2013) · Current Metabolomics · doi:10.2174/2213235x113019990004 · Cited by 39
Usefulness of Genetic Testing in PD and PD Trials: A Balanced Review
Gasser, T. (2015) · Journal of Parkinson’s Disease · doi:10.3233/jpd-140507 · Cited by 35
Self-citationThe Association Between ß-Glucocerebrosidase Mutations and Parkinsonism
Swan, M. C., & Saunders-Pullman, R. J. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0368-x · Cited by 39
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.